Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07503353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a phase I/II trial of SHB-02-CD19, T-cell expressing an anti-CD19 Chimeric-Antigen-Receptor (CAR) in patients with CD19 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.
Trial Details
NCT Number NCT07503353
Lead Sponsor Sheba Medical Center
Conditions
(from sponsor)		 B Cell Malignancies, Acute Lymphobkastic Leukemia, Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov